Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Structure in HIV-infected Individuals, Naive to Therapy, Who Are Starting Therapy for the First Time

NCT00192660 Phase 4 COMPLETED

This is a prospective, non-randomised, 48 week study of the effect of protease inhibitor (PI) containing and non-PI containing antiretroviral regimens on the expression of adipocyte specific genes, protein levels and cellular structure in HIV-infected individuals, naive to therapy, who are starting therapy for the first time.

Details

Lead sponsor	Kirby Institute
Phase	Phase 4
Status	COMPLETED
Enrolment	80
Start date	2003-02
Completion	2007-12

Conditions

• HIV-Associated Lipodystrophy Syndrome
• Cardiovascular Disease

Interventions

• Lamivudine
• Stavudine
• Didanosine
• Zidovudine
• Tenofovir
• Abacavir
• Efavirenz (EFV)
• Nevirapine
• Indinavir
• Saquinavir

Primary outcomes

• To investigate changes in adipocyte structure and function in HIV-infected individuals treated with antiretroviral therapy

Countries

Australia